Frontline treatment of diffuse large B-cell lymphoma: Beyond R-CHOP

Patrizia Mondello; Michael Mian

doi:10.1002/hon.2613

Frontline treatment of diffuse large B-cell lymphoma: Beyond R-CHOP

Hematol Oncol. 2019 Oct;37(4):333-344. doi: 10.1002/hon.2613. Epub 2019 Apr 26.

Authors

Patrizia Mondello^{1

2}, Michael Mian³

Affiliations

¹ Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, New York, USA.
² Department of Human Pathology, University of Messina, Messina, Italy.
³ Department of Hematology & CBMT, Ospedale di Bolzano, Bolzano, Italy.

PMID: 30938848
DOI: 10.1002/hon.2613

Abstract

Although the majority of patients with diffuse large B-cell lymphoma (DLBCL) can be cured with the standard immunochemotherapy R-CHOP, one-third of them relapses with a dismal outcome in most cases. In the recent years, remarkable advances have been achieved based on the discovery of molecular genetics in DLBCL. In addition to the major cell-of-origin designations of germinal center B-cell and activated B-cell subtypes, next-generation sequencing has unveiled the remarkable complexity of DLBCL and identified potential molecular targets for tailored therapies. Despite these findings, the current standard of care for DLBCL patients is still R-CHOP, and optimization of frontline therapy remains an important goal. In this review, we summarize recent updates on the evolution of frontline therapies for DLBCL.

Keywords: consolidation; diffuse large B-cell lymphoma; double-hit lymphoma; frontline therapy; maintenance.

Publication types

Review

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
B-Lymphocyte Subsets / drug effects
Clinical Trials as Topic
Combined Modality Therapy
Consolidation Chemotherapy
Cyclophosphamide / administration & dosage
DNA, Neoplasm / genetics
Doxorubicin / administration & dosage
Gene Expression Profiling
Genes, Neoplasm
Hematopoietic Stem Cell Transplantation
High-Throughput Nucleotide Sequencing
Humans
Immunotherapy*
Lymphoma, Large B-Cell, Diffuse / drug therapy*
Lymphoma, Large B-Cell, Diffuse / genetics
Lymphoma, Large B-Cell, Diffuse / pathology
Lymphoma, Large B-Cell, Diffuse / therapy
Maintenance Chemotherapy
Molecular Targeted Therapy*
Multicenter Studies as Topic
Neoplastic Stem Cells / classification
Neoplastic Stem Cells / drug effects
Prednisone / administration & dosage
Progression-Free Survival
Randomized Controlled Trials as Topic
Remission Induction
Rituximab / administration & dosage
Salvage Therapy
Vincristine / administration & dosage

Substances

DNA, Neoplasm
Rituximab
Vincristine
Doxorubicin
Cyclophosphamide
Prednisone

Supplementary concepts

CHOP protocol